Work

ABCL-023 frontMIND: A Phase III, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

Year: 2022

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(22)01488-4

Authors: Umberto Vitolo, Grzegorz S. Nowakowski, John M. Burke, Christopher P. Fox, Marek Trneny, Annalisa Chiappella, Maeve Waldron-Lynch, Nira Hadar, Alok Pachori, Georg Lenz

Institutions: Candiolo Cancer Institute, Mayo Clinic, Rocky Mountain Cancer Centers, Nottingham University Hospitals NHS Trust, Charles University, General University Hospital in Prague, Fondazione IRCCS Istituto Nazionale dei Tumori, University Hospital Münster

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4296468498

FWCI:

Cites:

Cited by:

Related to: 10